10th International Congress on Peritoneal Surface Malignancies

November 17 – 19, 2016 • Omni Shoreham Hotel • Washington, DC

Course Director:
Paul H. Sugarbaker, MD
MedStar Surgical Oncology, Washington, DC

Scientific Organizing Committee

David L. Bartlett, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA

Marcello Deraco, MD
Istituto Nazionale dei Tumori
Milan, ITALY

Olivier Gileen, MD, PhD
Hospitalet Lyon Sud
Lyon, FRANCE

Santiago Gonzalez-Moreno, MD, PhD
MD Anderson Cancer Center Madrid
Madrid, SPAIN

Yan Li, MD, PhD
Beijing Shijitan Hospital
Beijing, CHINA

Brendan J. Moran, MCh, FRCS, FRCSI
The North Hampshire Hospitals
Basingstoke, UNITED KINGDOM

David Morris, MD
St. George Hospital
Kogarah, AUSTRALIA

Pompilii Piso, MD, PhD
Hospital Barmerzie Brueker
Regensburg, GERMANY

Beate S. Rau, MD, PhD
Charité Campus Mitte University Hospital
Berlin, GERMANY

Vic Verwaal, MD
Aarhus University Hospital
Aarhus, DENMARK

Yutaka Yonemura, MD, PhD
Kishiwada Tokushukai Hospital
Oosaka, JAPAN

www.psogi2016.com
Thursday, November 17

SESSION I: Update on Clinical Trials in Colorectal Cancer
SESSION II: Update on Clinical Trials in Ovarian Cancer
SESSION III: Keynote Lecture, Debate & Best Abstracts Presentations
  - Keynote Lecture: Animal Models - What Can They Tell Us About the Management of Peritoneal Metastases?
  - Debate: Adjuvant HIPEC Is Superior/Inferior To Second-Look Surgery With HIPEC In High Risk Primary Colorectal Cancer For Peritoneal Metastases
  - Presentation of Best Abstracts (1-4)

SESSION IV: Debate & Case Presentations with Panel of Experts
  - Debate: CRS and HIPEC is/is not the Standard of Care for Selected Patients with Colorectal Peritoneal Metastases in the United States
  - Case Presentations: Prevention and Treatment of Peritoneal Metastases from Colorectal Cancer

Evening Networking Welcome Reception

Friday, November 18

Registration and Meet the Professor Breakfast Breakouts

SESSION V: Update on Clinical Trials in Gastric Cancer
SESSION VI: Update on National/International Peritoneal Metastases Registries
SESSION VII: Best Abstracts Presentations & Case Presentations
  - Presentation of Best Abstracts (5-8)
  - Case Presentations: Peritoneal Metastases from Gastric Cancer

SESSION VIII: Keynote Lecture, Debate & Case Presentations
  - Keynote Lecture: Current Treatment Options for Management of Gastric Cancer with Peritoneal Metastases
  - Debate: Recurrent Ovarian Cancer - CRS and HIPEC is/is not a Reasonable Treatment Option Now in Selected Patients
  - Case Presentations: CRS and HIPEC for Unusual Diseases

SESSION IX: Keynote Lecture, Debate & Case Presentations
  - Keynote Lecture: Progress in the Management of Primary and Recurrent Ovarian Cancer in Cordoba, Spain
  - Debate: Pharmacology and Clinical Data Show/Do Not Show, that Mitomycin C not 5-FU and High Dose Oxaiplatin is the Current Standard of Care for Peritoneal Metastases from Colon Cancer
  - Case Presentations: The Prevention and Treatment of Peritoneal Metastases from Ovarian Cancer

Evening Congress Banquet with Historical Documentary: 30 Years of Progress in Treating Peritoneal Metastases

Saturday, November 19

Meet the Professor Breakfast Breakouts

SESSION X: New Technologies to Optimize Management of Peritoneal Surface Malignancy
  - Keynote Lecture: Genomic Medicine as it Involves Peritoneal Metastases
  - Keynote Lecture: Bidirectional Adjuvant Normothermic Chemotherapy (BANCT) Long-Term for Management of Ovarian Cancer
  - Keynote Lecture: 90% of the Adverse Outcomes Occur in 10% of Patients. Can We Identify the High Risk Groups?
  - Case Presentations: Prevention and Treatment of Peritoneal Metastases from Appendiceal Cancer

Looking Ahead to the 2018 Congress in Paris

POST-CONFERENCE SATELLITE PROGRAMS
  Pharmacology of Chemotherapy Treatments for Peritoneal Metastases: Optimizing and Augmenting HIPEC
  Peritoneal Metastases Imaging

Visit www.psoji2016.com for the most updated program information and to register to attend